X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215035
https://health.economictimes.indiatimes.com/news/pharma/novartis-to-pay-30-million-to-health-plans-consumers-over-exforge-antitrust-claims/98197879
https://www.fiercepharma.com/pharma/novartis-pays-245m-settle-exforge-generic-pay-delay-lawsuits
https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-norliqva-the-first-and-only-fda-approved-liquid-solution-of-amlodipine-is-now-available-301559346.html
https://www.business-standard.com/article/companies/macleods-pharmaceuticals-recalls-products-in-us-for-manufacturing-issues-122031300189_1.html
http://www.koreabiomed.com/news/articleView.html?idxno=12631
https://psnc.org.uk/our-news/class-3-medicines-recall-amlodipine-10mg-tablets-accord-healthcare-limited/
https://www.nytimes.com/2020/07/01/business/Novartis-kickbacks-diabetes-heart-drugs.html
https://www.livemint.com/companies/news/drugs-for-tb-hypertension-and-antacids-amongst-those-failing-quality-tests-11577182667784.html
https://www.fiercepharma.com/pharma/novartis-sets-aside-700m-for-possible-kickback-lawsuit-settlement
https://www.biospace.com/article/newly-branded-azurity-wins-fda-approval-for-liquid-form-of-amlodipine/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211340
https://www.fiercepharma.com/pharma/big-pharma-hits-3b-payments-to-doctors-and-teaching-hospitals-cms
https://www.fiercepharma.com/pharma/court-document-filed-error-reveals-novartis-kickback-suit-settlement-talks-report
https://www.businesswire.com/news/home/20190430005302/en/Merck-Announces-First-Quarter-2019-Financial-Results/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-27-2019-1553661457.pdf
https://www.raps.org/news-and-articles/news-articles/2019/3/to-prevent-losartan-shortages-fda-allows-higher-i
https://www.pharmacompass.com/pdf/news/aurobindo-pharma-usa-inc-recall-expansion-of-38-lots-of-amlodipine-valsartan-tablets-usp-1551508583.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-23-2019-1548227584.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-receives-final-approvals-from-usfda-for-skin-ointment-heart-medicine/articleshow/67499638.cms
https://www.dnaindia.com/business/report-a-wave-of-drug-recalls-hits-indian-pharma-firms-in-us-2705817
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-usa-recalls-80-lots-of-blood-pressure-drug-from-america/articleshow/67335904.cms
https://www.pharmacompass.com/pdf/news/aurobindo-pharma-recalls-80-lots-of-amlodipine-valsartan-tablets-due-to-ndea-impurity-1546408381.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11192018103541
https://www.ema.europa.eu/documents/referral/sartans-article-31-referral-timetable-procedure_en.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11122018102457
https://www.pharmacompass.com/pdf/news/mylan-expands-voluntary-nationwide-recall-of-valsartan-tablets-due-to-trace-ndea-1544072295.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-5-2018-1544180983.pdf
https://www.fiercepharma.com/manufacturing/valsartan-recall-expands-to-mylan-teva-products
https://www.reuters.com/article/us-teva-pharm-ind-recall/teva-to-recall-certain-blood-pressure-medicine-in-u-s-idUSKCN1NW2HN
https://www.fiercepharma.com/manufacturing/valsartan-recall-expands-to-mylan-teva-products
https://www.pharmacompass.com/pdf/news/teva-recalls-amlodipinevalsartan-tablets-amlodipinevalsartanhydrochlorothiazide-1543384093.pdf
https://www.pharmacompass.com/pdf/news/mylan-recalls-valsartan-tablets-amlodipine-and-valsartan-tablets-and-valsartan-and-hydrochlorothiazide-tablets-1542877094.pdf
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-October-31-2018-1540974685.pdf
https://www.pharmacompass.com/pdf/news/fda-posts-laboratory-analysis-of-ndma-levels-in-recalled-valsartan-products-1539151946.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-5-2018-1536113909.pdf
https://www.dnaindia.com/business/report-torrent-pharmaceuticals-recalls-14-lots-of-valsartan-in-us-2651963
https://www.fiercepharma.com/manufacturing/tainted-valsartan-has-been-market-four-years-fda-discovers
https://www.pharmacompass.com/pdf/news/gattex-teduglutide-amlodipine-and-valsartan-tabs-shire-nps-pharm-v-par-pharma-et-al-1533038693.pdf
https://edition.cnn.com/2018/07/19/health/valsartan-recall-explainer/index.html
https://www.swissmedic.ch/swissmedic/en/home/news/mitteilungen/valsartane-recall-update-productoverview.html
Market Place
Share 
